MarketCap
Facebook
X
TelegramQuarterly report 2023-Q3
added 11-08-2023
Invitae Corporation Cash and Cash Equivalents 2011-2026 | NVTA
Annual Cash and Cash Equivalents Invitae Corporation
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 257 M | 923 M | 131 M | 151 M | 112 M | 12.1 M | 66.8 M | 73.2 M | 107 M | 43.1 M | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 923 M | 12.1 M | 188 M |
Quarterly Cash and Cash Equivalents Invitae Corporation
| 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 158 M | 223 M | 161 M | 257 M | 217 M | 304 M | 325 M | 923 M | 922 M | 1.11 B | 194 M | 131 M | 125 M | 125 M | 125 M | 151 M | 151 M | 151 M | 151 M | 112 M | 112 M | 112 M | 112 M | 12.1 M | 12.1 M | 12.1 M | 12.1 M | 66.8 M | 66.8 M | 66.8 M | 66.8 M | 73.2 M | 73.2 M | 73.2 M | 73.2 M | 107 M | 107 M | 107 M | 107 M | 43.1 M | - | - | - | 21.8 M | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.11 B | 12.1 M | 182 M |
Cash and Cash Equivalents of other stocks in the Diagnostics research industry
| Issuer | Cash and Cash Equivalents | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Akumin
AKU
|
59.4 M | - | -17.87 % | $ 25.9 M |  Canada |
|
Centogene N.V.
CNTG
|
19.1 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Brainsway Ltd.
BWAY
|
69.3 M | $ 24.33 | 5.28 % | $ 99.4 M |  Israel |
 |
Chembio Diagnostics
CEMI
|
18.2 M | - | 0.22 % | $ 16.8 M |  USA |
 |
Check-Cap Ltd.
CHEK
|
7.7 M | - | - | $ 9.42 M | Israel |
 |
Burning Rock Biotech Limited
BNR
|
1.9 B | $ 23.41 | 0.47 % | $ 252 M |  China |
 |
Biocept
BIOC
|
12.9 M | - | -13.05 % | $ 7.29 M | USA |
 |
Castle Biosciences
CSTL
|
120 M | $ 39.7 | 0.92 % | $ 1.1 B | USA |
 |
Co-Diagnostics
CODX
|
14.9 M | $ 6.0 | -3.07 % | $ 176 M | USA |
 |
Accelerate Diagnostics
AXDX
|
34.9 M | - | -61.36 % | $ 2.46 M | USA |
 |
DermTech
DMTK
|
36.7 M | - | -11.32 % | $ 2.94 M | USA |
 |
DexCom
DXCM
|
566 M | $ 70.68 | 4.87 % | $ 27.3 B | USA |
 |
BioNano Genomics
BNGO
|
9.17 M | $ 1.58 | - | $ 2.01 M | USA |
 |
Guardant Health
GH
|
526 M | $ 107.76 | -2.19 % | $ 13.2 B | USA |
 |
Global Cord Blood Corporation
CO
|
6.66 B | - | - | $ 399 M | China |
 |
Genetic Technologies Limited
GENE
|
11.7 M | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
176 M | - | 0.12 % | $ 80.1 M | China |
 |
Illumina
ILMN
|
1.13 B | $ 145.25 | 2.96 % | $ 23.1 B | USA |
 |
IQVIA Holdings
IQV
|
1.7 B | $ 241.11 | -0.55 % | $ 43.7 B | USA |
 |
CareDx, Inc
CDNA
|
82.2 M | $ 20.41 | 19.15 % | $ 1.1 B | USA |
 |
Danaher Corporation
DHR
|
2.08 B | $ 238.83 | 0.2 % | $ 175 B | USA |
 |
Celcuity
CELC
|
22.5 M | $ 104.34 | -2.95 % | $ 4.12 B | USA |
 |
DarioHealth Corp.
DRIO
|
36.8 M | $ 11.97 | -1.56 % | $ 340 M | Israel |
 |
Anixa Biosciences
ANIX
|
1.24 M | $ 3.19 | -5.62 % | $ 102 K | USA |
 |
Enzo Biochem
ENZ
|
52.4 M | - | -8.98 % | $ 14.8 K | USA |
 |
Lantheus Holdings
LNTH
|
913 M | $ 67.28 | -0.41 % | $ 4.66 B | USA |
 |
Exact Sciences Corporation
EXAS
|
601 M | $ 102.23 | 0.11 % | $ 18.9 B | USA |
 |
Fulgent Genetics
FLGT
|
55.1 M | $ 28.16 | 1.11 % | $ 851 M | USA |
 |
Medpace Holdings
MEDP
|
669 M | $ 599.7 | 0.79 % | $ 18.6 B | USA |
 |
Aspira Women's Health
AWH
|
13.3 M | - | -6.19 % | $ 10.5 M | USA |
 |
Motus GI Holdings
MOTS
|
4.96 M | - | -34.28 % | $ 263 K | Israel |
 |
Myriad Genetics
MYGN
|
102 M | $ 6.56 | -0.3 % | $ 594 M | USA |
 |
Charles River Laboratories International
CRL
|
195 M | $ 219.73 | -0.62 % | $ 11.3 B | USA |
 |
Heska Corporation
HSKA
|
157 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
12.2 M | - | -20.0 % | $ 1.06 M | USA |
 |
National Research Corporation
NRC
|
6.65 M | $ 20.3 | 2.94 % | $ 498 M | USA |
 |
Mettler-Toledo International
MTD
|
59.4 M | $ 1 486.95 | 0.1 % | $ 31.6 B |  Schweiz |
 |
Natera
NTRA
|
466 M | $ 233.65 | -0.28 % | $ 23 B | USA |
 |
ENDRA Life Sciences
NDRA
|
3.23 M | $ 4.51 | -3.01 % | $ 2.42 M | USA |
 |
Neogen Corporation
NEOG
|
129 M | $ 9.33 | -3.01 % | $ 2.02 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
549 M | $ 175.05 | 0.34 % | $ 19.4 B | USA |
|
Biodesix
BDSX
|
26.2 M | $ 8.2 | 50.18 % | $ 1.06 B | USA |
 |
Organovo Holdings
ONVO
|
11.3 M | - | -2.3 % | $ 19.4 M | USA |
 |
Laboratory Corporation of America Holdings
LH
|
1.52 B | $ 249.91 | -0.75 % | $ 21 B | USA |
 |
ICON Public Limited Company
ICLR
|
752 M | $ 180.43 | -0.52 % | $ 14.9 B |  Irlanda |
 |
IDEXX Laboratories
IDXX
|
288 M | $ 722.17 | 1.24 % | $ 59.6 B | USA |